Clinical Trial Update: Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes [Phase 4]

View source ↗

Summary

A Phase 4 trial of rifaximin in liver cirrhosis investigating endotoxin and haemostatic indexes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coagulation Disorders
• Endotoxemia
• Liver Cirrhosis
• Platelet Disorders

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: University of Roma La Sapienza | Conditions: Liver Cirrhosis, Coagulation Disorder | Phase 4 | Status: TERMINATED